×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CRSP – crispr therapeutics ag - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CRSP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
11:41 am
crsp
The Gene Revolution: Transforming Lives through Gene Editing Therapeutics [Yahoo! Finance]
Low
Report
The Gene Revolution: Transforming Lives through Gene Editing Therapeutics [Yahoo! Finance]
11/17
05:20 pm
crsp
CRISPR Therapeutics AG (CRSP): Among ARK Invest's Top Stock Picks for 2024 [Yahoo! Finance]
Low
Report
CRISPR Therapeutics AG (CRSP): Among ARK Invest's Top Stock Picks for 2024 [Yahoo! Finance]
11/16
06:06 am
crsp
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More [Yahoo! Finance]
Low
Report
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More [Yahoo! Finance]
11/14
08:57 am
crsp
Genome Editing Market Expected To Reach 30.78 Billion 2032, Growing at CAGR 17.18% | Introspective Market Research [Yahoo! Finance]
Medium
Report
Genome Editing Market Expected To Reach 30.78 Billion 2032, Growing at CAGR 17.18% | Introspective Market Research [Yahoo! Finance]
11/14
08:30 am
crsp
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
Medium
Report
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
11/7
08:08 am
crsp
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates [Yahoo! Finance]
Low
Report
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates [Yahoo! Finance]
11/7
08:00 am
crsp
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Low
Report
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
11/7
02:04 am
crsp
CRISPR Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
CRISPR Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at StockNews.com to a "sell" rating.
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2024
09:01 am
crsp
crispr therapeutics ag - common shares
BEAT
Report
0.6%
crispr therapeutics ag - common shares
8/5/2024
04:01 pm
crsp
crispr therapeutics ag - common shares
MISS
Report
-0.7%
crispr therapeutics ag - common shares
5/9/2024
04:02 pm
crsp
crispr therapeutics ag - common shares
BEAT
Report
-4.0%
crispr therapeutics ag - common shares
5/8/2024
04:11 pm
crsp
crispr therapeutics ag - common shares
BEAT
Report
-1.0%
crispr therapeutics ag - common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/13
05:35 pm
crsp
Form 4 CRISPR Therapeutics AG For: Nov 11 Filed by: Kulkarni Samarth
Medium
Report
Form 4 CRISPR Therapeutics AG For: Nov 11 Filed by: Kulkarni Samarth
11/12
09:41 am
crsp
Form 144 CRISPR Therapeutics AG Filed by: Kulkarni Samarth
Medium
Report
Form 144 CRISPR Therapeutics AG Filed by: Kulkarni Samarth
11/5
09:11 am
crsp
Form 10-Q CRISPR Therapeutics AG For: Sep 30
Low
Report
Form 10-Q CRISPR Therapeutics AG For: Sep 30
11/5
09:05 am
crsp
Form 8-K CRISPR Therapeutics AG For: Nov 05
Low
Report
Form 8-K CRISPR Therapeutics AG For: Nov 05
10/18
05:35 pm
crsp
Form 4 CRISPR Therapeutics AG For: Oct 16 Filed by: KASINGER JAMES R.
Low
Report
Form 4 CRISPR Therapeutics AG For: Oct 16 Filed by: KASINGER JAMES R.
10/18
05:35 pm
crsp
Form 4 CRISPR Therapeutics AG For: Oct 16 Filed by: Bruno Julianne
Low
Report
Form 4 CRISPR Therapeutics AG For: Oct 16 Filed by: Bruno Julianne
10/18
05:35 pm
crsp
Form 4 CRISPR Therapeutics AG For: Oct 16 Filed by: Patel Naimish
Low
Report
Form 4 CRISPR Therapeutics AG For: Oct 16 Filed by: Patel Naimish
10/18
05:35 pm
crsp
Form 4 CRISPR Therapeutics AG For: Oct 16 Filed by: Kulkarni Samarth
Low
Report
Form 4 CRISPR Therapeutics AG For: Oct 16 Filed by: Kulkarni Samarth
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/19
CRISPR Therapeutics down 4% premarket on initial CTX001 data [Seeking Alpha]
19.1%
2/28 Can CRISPR Therapeutics Double Your Money in 2020? [The Motley Fool] 13.1%
10/28 Q3/2019 9/30/2019 EPS 2.400 ZacksConsensus N/A ActVsEst N/A - N/A 12.5%
8/5 Form 4 CRISPR Therapeutics AG For: Aug 01 Filed by: Ho Tony W 7.5%
2/7 First CRISPR Gene Editing Trial in Cancer Patients Shows Promising Results [The Motley Fool] 6.8%
12/2 Form 4 CRISPR Therapeutics AG For: Dec 01 Filed by: Kulkarni Samarth 6.3%
11/22 Form 8-K CRISPR Therapeutics AG For: Nov 19 6.1%
10/30 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 5.9%
6/6 Form 8-K CRISPR Therapeutics AG For: Jun 06 5.6%
4/24 Form DEF 14A CRISPR Therapeutics AG For: Jun 11 5.5%
2/28 Can CRISPR Therapeutics Double Your Money in 2020? [The Motley Fool] 13.1%
10/28 Q3/2019 9/30/2019 EPS 2.400 ZacksConsensus N/A ActVsEst N/A - N/A 12.5%
8/5 Form 4 CRISPR Therapeutics AG For: Aug 01 Filed by: Ho Tony W 7.5%
2/7 First CRISPR Gene Editing Trial in Cancer Patients Shows Promising Results [The Motley Fool] 6.8%
12/2 Form 4 CRISPR Therapeutics AG For: Dec 01 Filed by: Kulkarni Samarth 6.3%
11/22 Form 8-K CRISPR Therapeutics AG For: Nov 19 6.1%
10/30 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 5.9%
6/6 Form 8-K CRISPR Therapeutics AG For: Jun 06 5.6%
4/24 Form DEF 14A CRISPR Therapeutics AG For: Jun 11 5.5%
TOP News Decliners
11/20
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
-10.6%
3/31 Form 8-K CRISPR Therapeutics AG For: Mar 31 -10.4%
8/3 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -10.2%
12/27 Form 8-K CRISPR Therapeutics AG For: Dec 27 -7.5%
12/6 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Wells Fargo & Co. -7.1%
2/21 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -6.5%
10/1 CRISPR Therapeutics to Present at Upcoming Investor Conferences -6.3%
9/25 Is CRISPR Therapeutics a Buy? [The Motley Fool] -5.9%
2/13 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock. -5.6%
6/19 Form 4 CRISPR Therapeutics AG For: Jun 17 Filed by: Kulkarni Samarth -5.6%
3/31 Form 8-K CRISPR Therapeutics AG For: Mar 31 -10.4%
8/3 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -10.2%
12/27 Form 8-K CRISPR Therapeutics AG For: Dec 27 -7.5%
12/6 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Wells Fargo & Co. -7.1%
2/21 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -6.5%
10/1 CRISPR Therapeutics to Present at Upcoming Investor Conferences -6.3%
9/25 Is CRISPR Therapeutics a Buy? [The Motley Fool] -5.9%
2/13 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock. -5.6%
6/19 Form 4 CRISPR Therapeutics AG For: Jun 17 Filed by: Kulkarni Samarth -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: